22-23 NeoCOAST-2

About this trial

NeoCOAST-2 is a Phase 2, open-label, multicentre, randomised, two-arm study of
durvalumab + monalizumab / oleclumab + CTX. The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab or AZD0171 and platinum doublet chemotherapy; or MEDI5752 in combination with platinum doublet chemotherapy or datopotamab deruxtecan (Dato-DXd) in combination with durvalumab and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.

Patient Profile

  1. Newly diagnosed and previously untreated NSCLC.
  2. Resectable, Stage IIA to Stage IIIA (per IASLC Staging).
  3. ECOG PS 0-1.
  4. Tumour samples must be available or obtainable.
  5. Surgery may be lobectomy, sleeve resection or bilobectomy, no pneumonectomy, segmentectomies or wedge resection.
  6. FEV1 of 1.0 L and DLCO >40%

Where’s this trial being run?

Beaumont Hospital, St James’s Hospital, University Hospital Galway, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: 22-23 NeoCOAST-2
Number: 22-23
Full Title:

A Phase II Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIA) Non-small Cell Lung Cancer

Principal Investigator: Prof Jarushka Naidoo
Type: Industry Sponsored


Recruitment Started: Global: Yes
Ireland: Yes
Global Recruitment Target: 350
Ireland Recruitment Target: 15+